Youtor
Introducing AVEIR DR – The World’s First Dual Chamber Leadless Pacemaker System
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=2-8ph--bj6c
The world’s first and only dual chamber leadless pacing system is now FDA approved: AVEIR DR from Abbott.¹ • This groundbreaking new pacing technology features:² • 1. Beat-to-Beat Atrioventricular (AV) Synchrony made possible with industry-first, proprietary implant-to-implant (i2i) communication. • 2. An Upgradeable System: to tailor patient therapy over time by giving physicians the option to upgrade to dual chamber as needed. • 3. Long-term retrieval, with a success rate above 88% for AVEIR VR’s predicate device through 9 years regardless of implant duration.³ • AVEIR DR offers the clinical benefits of traditional dual chamber pacemakers without the associated lead and pocket-related complications including infection, lead fracture, lead insulation problems, skin erosion, keloid formation and no visible scarring or movement restrictions.⁴,⁵ • Discover the leadless advantage today. • To learn more, please visit: https://www.cardiovascular.abbott/us/... • To view important safety information, visit: https://www.cardiovascular.abbott/us/... • References: • 1. AVEIR DR FDA Approval • 2. AVEIR Leadless Pacemakers and Delivery Catheter IFU, ARTEN600284235. • 3. Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals: A Worldwide Nanostim Experience out of 9y. Presented at: APHRS 2022; Nov 18-20, 2022; Singapore. • 4. Sattar et al. Complications of leadless vs conventional (lead) artificial pacemakers - a retrospective review. Journal of community hospital internal medicine perspectives vol. 10,4 328-333. 2 Aug. 2020, doi:10.1080/20009666.2020.1786901 • 5. Reddy VY, Cantillon DJ, John IP . San Francisco, CA: 6 May 2016. A comparative study of acute and mid-term complications of leadless vs transvenous pacemakers. Late-Breaking Clinical Trials II. Presented at Heart Rhythm Society 2016; pp. 02–04. Abstract LBCT. • MAT-2307648 v2.0 | Item approved for U.S. use
#############################
